Abiopharma

News list

Li Dean Y 🟡 adjusted position in 2.3K shares (1 derivative) of Merck & Co., Inc. (MRK) at $110.03 Transaction Date: Apr 29, 2026 | Filing ID: 000088

Full text

News bot May 1, 2026, 9:45 p.m.
🔍 Li Dean Y (Executive)

Company: Merck & Co., Inc. (MRK)

Report Date: 2026-04-29
Transaction Summary:
- Total transactions: 3
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 4,722
- Total shares sold: 7,048
Detailed Transactions and Holdings:
- Acquired 4,722 shares of Common Stock at $110.03 per share (Direct)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 96,757.05 | transaction_form_type: 4
- Sold 2,326 shares of Common Stock at $110.03 per share (Direct)
  Date: 2026-04-29 | Code: F | equity_swap_involved: 0 | shares_owned_after: 94,431.05 | transaction_form_type: 4
- Sold 4,722 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-29 | Code: M | Expires: 2028-04-29 | Exercise: 2026-04-29 | equity_swap_involved: 0 | shares_owned_after: 9,444.00 | transaction_form_type: 4 | Footnotes: F1, F2
Footnotes:
- F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
- F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028.